<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87469">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02066051</url>
  </required_header>
  <id_info>
    <org_study_id>13-003814</org_study_id>
    <nct_id>NCT02066051</nct_id>
  </id_info>
  <brief_title>Intense Pulsed Light (IPL) and Meibomian Gland Expression to Treat Ocular Rosacea Secondary to Inactive Chronic Ocular GVHD</brief_title>
  <official_title>Intense Pulsed Light (IPL) and Meibomian Gland Expression to Treat Ocular Rosacea Secondary to Inactive Chronic Ocular Graft Versus Host Disease (GVHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Is Intense Pulsed Light (IPL) treatment and eyelid meibomian gland manual expression safe
      and effective for allogeneic stem cell transplant patients with ocular rosacea in the
      setting of quiescent graft-versus-host disease?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of participants who respond to IPL</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Identify 10 allogeneic stem cell transplant/GVHD subjects with severe dry eye symptoms from ocular rosacea unresponsive to conventional management and treat with monthly IPL and meibomian gland expression over 4 months with an 8 month monitoring period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants who experience adverse events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>monitor safety during treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>GVHD</condition>
  <condition>Ocular Rosacea</condition>
  <arm_group>
    <arm_group_label>IPL Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 allogeneic stem cell transplant/GVHD subjects with severe dry eye symptoms from ocular rosacea unresponsive to conventional management will be treated with monthly over 4 months with IPL and meibomian gland expression</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>IPL</intervention_name>
    <description>Intense Pulsed Light (IPL) treatment</description>
    <arm_group_label>IPL Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ocular rosacea with inactive GVHD

        Exclusion Criteria:

          -  Active GVHD

          -  Facial laser treatment

          -  Accutane exposure

          -  Inability to wear sun protection factor (SPF) 30 sunscreen and avoid sun exposure

          -  Inability to meet study requirements
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joanne Shen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joanne Shen, MD</last_name>
      <phone>480-301-8000</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Joanne F. Shen, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Ophthalmology</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rosacea</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
